Lumexa Imaging Holdings, Inc. LMRI
10.21
0.33
3.34%
as of 25 Sep
- Market cap
- $949.2M
- P/E
- 0.0×
Follow LMRI
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | — | — |
+3 more TTM periods Free account |
|
| (5.51%) | (3.51%) | 0.00% | — | ||
ROIC |
48.10% | 48.32% | 0.00% | 0.00% | |
Return on Tangible Assets |
(21.30%) | (28.17%) | 0.00% | — | |
Average Days of Receivables |
35.09 | 31.75 | 0.00 | — | |
Free Cash Flow per Share |
0.16 | (0.24) | (0.10) | 0.14 | |
Free Cash Flow |
14.93 | (22.88) | (7.22) | 10.04 | |
Capital Expenditures |
(39.95) | (31.00) | (53.13) | (56.31) | |
Piotroski F-Score |
1.00 | 1.00 | 0.00 | — | |
| Other line items | |||||
Cash ROIC |
3.52% | 0.53% | 3.04% | 0.00% | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
11.44 | 0.00 | 0.00 | — | |
Days of Inventory on Hand |
0.00 | — | — | — | |
Tax Rate |
(0.01) | 0.00 | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
4.52% | 0.00% | — | — | |
Share Based Compensation of Revenue |
2.22% | 0.00% | — | — | |
Interest Coverage |
0.00 | 0.00 | — | — | |
Operating CF/Net income |
(1.10) | (0.13) | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.68 | 0.70 | 1.06 | 0.00 | |
Capex/Depreciation |
(0.38) | (0.29) | (0.35) | (0.30) | |
Revenue per Share |
18.66 | 18.46 | 0.00 | 0.00 | |
Operating CF per Share |
0.57 | 0.08 | 0.65 | 0.95 | |
Capex per Share |
(0.42) | (0.32) | (0.75) | (0.81) | |
Capex to Sales |
0.02 | 0.02 | 0.00 | 0.00 | |
Net Profit Margin |
(2.78%) | (3.40%) | — | — |
Columns are period end dates